Termine {BACK}
Pressemitteilungen {BACK}
Pressespiegel {BACK}
IP Infos {BACK}
Life Sciences {BACK}
Stellenangebote {BACK}


BIO Europe 2016: Liquid Biopsy based early Breast Cancer Detection

Scientists of the University Medical Center of Aachen have developed a blood-based test for detecting breast cancer and its pre-invasive stages. PROvendis will present these novelty at the BIO Europe.

A so-called biomarker panel of three specific gene promoter regions has been put together, of which the pattern and intensity of methylation is ana-lysed. DNA methylation is an epigenetic modification of the genome, which often occurs at specific sites during cancer development and progression. The blood sample for the test can easily be taken by any general practitio-ner. Consequently, such a test should likely find much higher acceptance in women and may even allow broadening of preventive screening to elderly women over seventy years as well as to younger women under fifty years, who currently are not invited to mammography screening.

The use of such tests becomes obvious in comparison with developments in colorectal cancer screening. In April this year, a blood-based early detection system for that type of cancer has been approved by the Food and Drug Administration (FDA). The newly developed breast cancer blood test may be applied in an analogous way for routine breast cancer screening. Both colon and breast cancer tests have similar sensitivity and specificity, which may qualify the breast cancer test for a future approval as well.

On behalf of the of the University Medical Center of Aachen, PROvendis commercializes this innovative approach to industrial partners: we offer interested companies a patent license as well as a research collaboration with licensing option.

Download [74 KB]
Quelle: PROvendis GmbH